Perspective Therapeutics (CATX) Income from Discontinued Operations (2022 - 2026)

Perspective Therapeutics has disclosed Income from Discontinued Operations across 5 years of filings, most recently posting $197000.0 for Q2 2026.

• In Q2 2026, Income from Discontinued Operations fell 61.67% year-over-year to $197000.0; the TTM figure through Jun 2026 stood at $711000.0 (up 38.33% YoY), while the FY2025 annual figure was $514000.0, up 154.16% from the prior year.
• Income from Discontinued Operations came in at $197000.0 for Q2 2026 at Perspective Therapeutics, down from $514000.0 in the prior quarter.
• In the past five years, Income from Discontinued Operations ranged from a high of $514000.0 in Q2 2025 to a low of -$5.2 million in Q4 2023.
• Average Income from Discontinued Operations over 5 years is -$1.3 million, with a median of -$784000.0 recorded in 2023.
• Year-over-year, Income from Discontinued Operations tumbled 127.82% in 2023 and soared 204.9% in 2025.
• Over 5 years, Income from Discontinued Operations stood at -$2.3 million in 2022, then plunged by 127.82% to -$5.2 million in 2023, then jumped by 90.55% to -$490000.0 in 2024, then soared by 204.9% to $514000.0 in 2025, then slumped by 61.67% to $197000.0 in 2026.
• Per Business Quant data, the three most recent Income from Discontinued Operations figures were $197000.0 in Q2 2026, $514000.0 in Q2 2025, and -$490000.0 in Q2 2024.